Research programme: tetravalent dengue vaccine - Kaketsuken

Drug Profile

Research programme: tetravalent dengue vaccine - Kaketsuken

Alternative Names: KD-382

Latest Information Update: 10 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kaketsuken
  • Developer Kaketsuken; Mahidol University
  • Class Dengue vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Dengue

Most Recent Events

  • 10 Jul 2018 Preclinical trials in Dengue in Japan (unspecified route)
  • 19 Jun 2018 Kaketsuken plans a phase I trial of attenuated Dengue vaccine (KD 382) (In Adults) (ACTRN12618001027202)
  • 16 Sep 2014 Kaketsuken receives a grant from Global Health Innovative Technology Fund for vaccine development in Dengue
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top